Criteria to qualify for study: Drug used in study:
  • At least two prior treatment regimens with progression while on Ibrutinib.

CLL46

A Phase 1/2 Multicenter study evaluating the safely and efficacy of KTE-C19 in adult subjects with relapsed/refractory Chronic Lymphocytic Lymphoma.
Criteria to qualify for study: Drug used in study:
  • First line treatment
  • Low blast count

MDS 21
Phase 3, Randomized, Controlled, Open label, Clinical Study of Pevonedistat Plus Azacitidine versus single agent Azacitidine as First-Line treatment for patients with higher risk Myelodysplatic Syndrome, Chronic Myelomonocytic Leukemia, of Low Blast Acute Myelogenous Leukemia.